Sino Biopharmaceutical (SBMFF) Stock Price, News & Analysis

Company Overview

Sino Biopharmaceutical (OTCMKTS:SBMFF) is an integrated pharmaceutical company headquartered in Hong Kong that focuses on research, development, manufacturing and distribution of a broad portfolio of pharmaceutical products. Established in 2000 as a spin-off from the Sino Group, the company has grown to become one of the leading players in the Greater China pharmaceutical market. Its product range spans both traditional Chinese medicines and Western chemical drugs, catering to a diverse set of therapeutic areas including cardiovascular, oncology, respiratory, diabetes and immunology.

The company’s product offerings comprise prescription drugs, over-the-counter remedies and health supplements. Key products include patented traditional formulations such as ginkgo leaf extracts and Danshen (Salvia miltiorrhiza) dripping pills, alongside modern small-molecule chemical drugs. In addition to in-house R&D capabilities, Sino Biopharmaceutical maintains multiple GMP-certified manufacturing facilities and a network of packaging and logistics operations to ensure consistent quality and supply chain efficiency.

Geographically, Sino Biopharmaceutical serves patients and healthcare professionals across Mainland China, Hong Kong, Macao and Southeast Asia. It has established a broad sales and distribution network that leverages both direct sales forces and partnerships with local distributors. This regional footprint is supported by strategic collaborations with academic institutions and research organizations to accelerate the development of innovative therapies tailored to local market needs.

Under the guidance of a seasoned executive leadership team with deep expertise in pharmaceuticals and biopharma, the company continues to invest in pipeline expansion and commercialization. Emphasizing quality control, regulatory compliance and sustainable growth, Sino Biopharmaceutical aims to address evolving healthcare challenges in its core markets while pursuing opportunities for global expansion through partnerships and licensing initiatives.

Key Stats

• Today's Range: $0.68 to $0.68
• 50-Day Range: $0.49 to $0.73
• 52-Week Range: $0.32 to $0.77
• Volume: N/A
• Average Volume: 2,575 shs
• Market Capitalization: $12.82 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SBMFF Stock Analysis - Frequently Asked Questions

How have SBMFF shares performed this year?

Sino Biopharmaceutical's stock was trading at $0.4113 on January 1st, 2025. Since then, SBMFF stock has increased by 65.9% and is now trading at $0.6824.

How do I buy shares of Sino Biopharmaceutical?

Shares of SBMFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/05/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SBMFF
• Previous Symbol: NASDAQ:SBMFF
• CIK: 1604982
• Web: www.sinobiopharm.com
• Phone: 852-2802-9886
• Fax: 852-2880-0847
• Employees: 25,806
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,791,220,000
• Free Float: N/A
• Market Cap: $12.82 billion
• Optionable: Not Optionable
• Beta: 0.60